1. Adjuvant anti‐PD‐1 antibody treatment in stage III/IV melanoma: real‐world experience and health economic considerations. (13th July 2021) Authors: Koelblinger, Peter; Hoellwerth, Magdalena; Dernoscheg, Marie‐Therese; Koch, Lukas; Richtig, Erika; Wanner, Marina; Nguyen, Van‐Anh; Ostermann, Herwig; Bauer, Johann W.; Laimer, Martin Journal: Journal der Deutschen Dermatologischen Gesellschaft Issue: Volume 19:Number 8(2021) Page Start: 1186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Issue 5 (May 2021) Authors: Bottomley, Andrew; Coens, Corneel; Mierzynska, Justyna; Blank, Christian U; Mandalà, Mario; Long, Georgina V; Atkinson, Victoria G; Dalle, Stéphane; Haydon, Andrew M; Meshcheryakov, Andrey; Khattak, Adnan; Carlino, Matteo S; Sandhu, Shahneen; Puig, Susana; Ascierto, Paolo A; Larkin, James; Loriga... Journal: Lancet oncology Issue: Volume 22:Issue 5(2021) Page Start: 655 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Adjuvante Anti‐PD‐1‐Antikörpertherapie bei Stadium‐III/IV‐Melanom: Anwendungsdaten aus der klinischen Routine und gesundheitsökonomische Aspekte. (13th August 2021) Authors: Koelblinger, Peter; Hoellwerth, Magdalena; Dernoscheg, Marie‐Therese; Koch, Lukas; Richtig, Erika; Wanner, Marina; Nguyen, Van‐Anh; Ostermann, Herwig; Bauer, Johann W.; Laimer, Martin Journal: Journal der Deutschen Dermatologischen Gesellschaft Issue: Volume 19:Number 8(2021) Page Start: 1186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Awareness of predatory journals and open access among medical oncologists: results of an online survey. Issue 6 (27th November 2019) Authors: Richtig, Georg; Richtig, Erika; Böhm, Alexandra; Oing, Christoph; Bozorgmehr, Farastuk; Kruger, Stephan; Kiesewetter, Barbara; Zielinski, Christoph; Berghoff, Anna S Journal: ESMO open Issue: Volume 4:Issue 6(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Bimatoprost 0.3 mg/ml ophthalmic solution for lash growth – Pilot study, half side trail. (2015) Authors: Moore, Dana; Kopera, Daisy; Richtig, Erika Journal: Global dermatology Issue: Volume 2:Number 3(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Einfluss der Covid‐19‐Pandemie auf die dermatoonkologische Versorgung in Österreich. (26th July 2020) Authors: Koelblinger, Peter; Nguyen, Van Anh; Hoeller, Christoph; Richtig, Erika Journal: Journal der Deutschen Dermatologischen Gesellschaft Issue: Volume 18:Number 7(2020) Page Start: 778 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy. (November 2018) Authors: Menzer, Christian; Beedgen, Bernd; Rom, Joachim; Duffert, Christin M.; Volckmar, Anna-Lena; Sedlaczek, Oliver; Richtig, Erika; Enk, Alexander; Jäger, Dirk; Hassel, Jessica C. Journal: European journal of cancer Issue: Volume 104(2018) Page Start: 239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. New insights into oculodermal nevogenesis and proposal for a new iris nevus classification. Issue 5 (30th October 2014) Authors: Schwab, Christoph; Zalaudek, Iris; Mayer, Christoph; Riedl, Regina; Wackernagel, Werner; Juch, Herbert; Aigner, Birgit; Brunasso, Alexandra Maria; Langmann, Gerald; Richtig, Erika Journal: British journal of ophthalmology Issue: Volume 99:Issue 5(2015) Page Start: 644 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. (September 2018) Authors: Carlino, Matteo S.; Long, Georgina V.; Schadendorf, Dirk; Robert, Caroline; Ribas, Antoni; Richtig, Erika; Nyakas, Marta; Caglevic, Christian; Tarhini, Ahmed; Blank, Christian; Hoeller, Christoph; Bar-Sela, Gil; Barrow, Catherine; Wolter, Pascal; Zhou, Honghong; Emancipator, Kenneth; Jensen, Erin... Journal: European journal of cancer Issue: Volume 101(2018) Page Start: 236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. (November 2017) Authors: Petrella, Teresa M.; Robert, Caroline; Richtig, Erika; Miller, Wilson H.; Masucci, Giuseppe V.; Walpole, Euan; Lebbe, Celeste; Steven, Neil; Middleton, Mark R.; Hille, Darcy; Zhou, Wei; Ibrahim, Nageatte; Cebon, Jonathan Journal: European journal of cancer Issue: Volume 86(2017) Page Start: 115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗